Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HROW NASDAQ:TENX NYSE:TRLV NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$41.53-0.7%$37.71$28.54▼$54.85$1.55B0.26755,429 shs143,724 shsTENXTenax Therapeutics$15.47-3.2%$12.72$5.77▼$19.40$407.53M0.92635,236 shs531,628 shsTRLVTrulieve Cannabis$8.95-1.0%$0.00$4.00▼$13.28$1.72BN/A626,014 shs295,192 shsVIRVir Biotechnology$9.57-1.6%$9.36$4.16▼$11.66$1.62B1.622.66 million shs641,836 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow-1.58%-6.94%+11.08%+10.35%+19.70%TENXTenax Therapeutics-8.95%-1.72%+39.20%+8.12%+173.91%TRLVTrulieve Cannabis+4.43%+1.37%+895,899,900.00%+895,899,900.00%+895,899,900.00%VIRVir Biotechnology-2.41%-2.99%+12.89%-3.28%+72.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$41.53-0.7%$37.71$28.54▼$54.85$1.55B0.26755,429 shs143,724 shsTENXTenax Therapeutics$15.47-3.2%$12.72$5.77▼$19.40$407.53M0.92635,236 shs531,628 shsTRLVTrulieve Cannabis$8.95-1.0%$0.00$4.00▼$13.28$1.72BN/A626,014 shs295,192 shsVIRVir Biotechnology$9.57-1.6%$9.36$4.16▼$11.66$1.62B1.622.66 million shs641,836 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow-1.58%-6.94%+11.08%+10.35%+19.70%TENXTenax Therapeutics-8.95%-1.72%+39.20%+8.12%+173.91%TRLVTrulieve Cannabis+4.43%+1.37%+895,899,900.00%+895,899,900.00%+895,899,900.00%VIRVir Biotechnology-2.41%-2.99%+12.89%-3.28%+72.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHROWHarrow 2.64Moderate Buy$69.4367.20% UpsideTENXTenax Therapeutics 2.86Moderate Buy$38.00145.57% UpsideTRLVTrulieve Cannabis 1.50ReduceN/AN/AVIRVir Biotechnology 2.89Moderate Buy$20.88118.24% UpsideCurrent Analyst Ratings BreakdownLatest TENX, TRLV, VIR, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/2/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/30/2026TENXTenax Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026TENXTenax Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$35.006/22/2026TENXTenax Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00 ➝ $40.006/22/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/18/2026TRLVTrulieve Cannabis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026TRLVTrulieve Cannabis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)6/12/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $50.006/11/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.006/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHROWHarrow$272.30M5.69$0.84 per share49.15$1.41 per share29.45TENXTenax TherapeuticsN/AN/AN/AN/A$10.42 per shareN/ATRLVTrulieve Cannabis$1.17B1.47N/AN/AN/A∞VIRVir Biotechnology$68.56M23.53N/AN/A$5.50 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHROWHarrow-$5.14M-$0.41N/A19.22N/A-5.57%19.59%2.26%8/10/2026 (Estimated)TENXTenax Therapeutics-$52.60M-$1.40N/AN/AN/AN/A-56.32%-53.12%8/12/2026 (Estimated)TRLVTrulieve CannabisN/AN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest TENX, TRLV, VIR, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026HROWHarrow-$0.23N/AN/AN/A$70.96 millionN/A8/5/2026Q2 2026VIRVir Biotechnology$0.3326N/AN/AN/A$135.88 millionN/A5/12/2026Q1 2026TENXTenax Therapeutics-$0.40-$0.35+$0.05-$0.35N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHROWHarrowN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ATRLVTrulieve CannabisN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHROWHarrow10.302.482.30TENXTenax TherapeuticsN/A14.5214.52TRLVTrulieve CannabisN/AN/AN/AVIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHROWHarrow72.76%TENXTenax Therapeutics1.67%TRLVTrulieve CannabisN/AVIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipHROWHarrow12.80%TENXTenax Therapeutics10.81%TRLVTrulieve Cannabis3.79%VIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHROWHarrow18037.28 million32.50 millionOptionableTENXTenax Therapeutics926.52 million23.66 millionNot OptionableTRLVTrulieve Cannabis9,000192.31 millionN/AN/AVIRVir Biotechnology580168.65 million163.76 millionOptionableTENX, TRLV, VIR, and HROW HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A.July 13 at 3:51 AM | marketbeat.comY Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIRJuly 12 at 1:51 PM | marketbeat.comVir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SAJuly 3, 2026 | marketbeat.comOP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIRJune 30, 2026 | marketbeat.comWhy Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps?June 29, 2026 | kalkinemedia.comKVir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline FocusJune 22, 2026 | kalkinemedia.comKVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 22, 2026 | marketbeat.comVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10, 2026 | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10, 2026 | businesswire.comBarclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 20262 Space and Defense Stocks Turning Backlogs Into Revenue GrowthBy Nathan Reiff | June 25, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 20263 Rate-Ready Stocks for the New Fed Chair’s First Big TestBy Chris Markoch | June 16, 2026Drone Stocks Are Down, But Defense Backlogs Tell a Different StoryBy Thomas Hughes | July 8, 2026TENX, TRLV, VIR, and HROW Company DescriptionsHarrow NASDAQ:HROW$41.52 -0.29 (-0.68%) As of 12:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Tenax Therapeutics NASDAQ:TENX$15.47 -0.51 (-3.17%) As of 12:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Trulieve Cannabis NYSE:TRLV$8.95 -0.09 (-1.00%) As of 12:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.Vir Biotechnology NASDAQ:VIR$9.56 -0.16 (-1.59%) As of 12:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Energy Stocks Racing to Fix AI's Power Problem No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings The Bond Market Just Sent Amazon a Message Investors Shouldn’t Ignore Insiders Sell 2 AI Enablers: Investors Can Buy Into Their Futures These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending These 3 Stocks Are Beating the Market in 2026 and Just Announced Hefty Dividend Increases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
